@article{hamai_hemoglobin_2014,
	title = {Hemoglobin level influences tumor response and survival after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma},
	volume = {38},
	issn = {1432-2323},
	doi = {10.1007/s00268-014-2486-2},
	abstract = {BACKGROUND

Neoadjuvant chemoradiotherapy (nCRT) followed by esophagectomy confers a survival benefit on patients with esophageal cancer. However, nCRT might be less meaningful for poor responders. Thus, being able to predict responses would help ensure the selection of optimal therapy.


METHODS

We reviewed data from 123 patients with esophageal squamous cell carcinoma (ESCC) who underwent nCRT that comprised concurrent radiation (40 Gy) and chemotherapy followed by esophagectomy. We assessed associations between clinical and blood data obtained before starting nCRT and the pathologic response.


RESULTS

We compared good (Japan Esophageal Society response evaluation criteria grades 3/2; n = 89, 72.4\%) and poor (grades 1/0; n = 34, 27.6\%) responders. Performance status (p = 0.02), hemoglobin level (p = 0.005), and platelet counts (p = 0.03) were statistically significant pretherapeutic factors for a response to nCRT. Multivariable analysis subsequently selected the hemoglobin level (odds ratio 1.52; 95\% confidence interval 1.08-2.15; p = 0.02) as the sole independent predictor. Receiver operating characteristic curves showed that the optimal cutoff for pretherapeutic hemoglobin was 13 g/dl for predicting a response. We found that 48.8 and 17.1\% of patients with hemoglobin level ≤13 and {\textgreater}13 g/dl, respectively, were poor responders (p = 0.0002), with 5-year overall survival rates of 40.9 and 58.9\%, respectively (p = 0.048).


CONCLUSIONS

Pretherapeutic hemoglobin levels can influence responses and survival after nCRT for ESCC. Thus, hemoglobin levels can serve as a useful marker for tailoring optimal therapies for individual patients with advanced ESCC.},
	number = {8},
	journal = {World journal of surgery},
	author = {Hamai, Yoichi and Hihara, Jun and Taomoto, Junya and Yamakita, Ichiko and Ibuki, Yuta and Okada, Morihito},
	month = aug,
	year = {2014},
	pmid = {24615604},
	keywords = {Adult, Aged, Biomarkers, Tumor, Carcinoma, Squamous Cell, Chemoradiotherapy, Combined Modality Therapy, Esophageal Neoplasms, Esophagectomy, Female, Hemoglobins, Humans, Male, Middle Aged, Neoadjuvant Therapy, Retrospective Studies, Survival Rate, Treatment Outcome},
	pages = {2046--2051}
}

{"_id":"xFo8Rq3CHnpRvppHZ","bibbaseid":"hamai-hihara-taomoto-yamakita-ibuki-okada-hemoglobinlevelinfluencestumorresponseandsurvivalafterneoadjuvantchemoradiotherapyforesophagealsquamouscellcarcinoma-2014","authorIDs":[],"author_short":["Hamai, Y.","Hihara, J.","Taomoto, J.","Yamakita, I.","Ibuki, Y.","Okada, M."],"bibdata":{"bibtype":"article","type":"article","title":"Hemoglobin level influences tumor response and survival after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma","volume":"38","issn":"1432-2323","doi":"10.1007/s00268-014-2486-2","abstract":"BACKGROUND Neoadjuvant chemoradiotherapy (nCRT) followed by esophagectomy confers a survival benefit on patients with esophageal cancer. However, nCRT might be less meaningful for poor responders. Thus, being able to predict responses would help ensure the selection of optimal therapy. METHODS We reviewed data from 123 patients with esophageal squamous cell carcinoma (ESCC) who underwent nCRT that comprised concurrent radiation (40 Gy) and chemotherapy followed by esophagectomy. We assessed associations between clinical and blood data obtained before starting nCRT and the pathologic response. RESULTS We compared good (Japan Esophageal Society response evaluation criteria grades 3/2; n = 89, 72.4%) and poor (grades 1/0; n = 34, 27.6%) responders. Performance status (p = 0.02), hemoglobin level (p = 0.005), and platelet counts (p = 0.03) were statistically significant pretherapeutic factors for a response to nCRT. Multivariable analysis subsequently selected the hemoglobin level (odds ratio 1.52; 95% confidence interval 1.08-2.15; p = 0.02) as the sole independent predictor. Receiver operating characteristic curves showed that the optimal cutoff for pretherapeutic hemoglobin was 13 g/dl for predicting a response. We found that 48.8 and 17.1% of patients with hemoglobin level ≤13 and \\textgreater13 g/dl, respectively, were poor responders (p = 0.0002), with 5-year overall survival rates of 40.9 and 58.9%, respectively (p = 0.048). CONCLUSIONS Pretherapeutic hemoglobin levels can influence responses and survival after nCRT for ESCC. Thus, hemoglobin levels can serve as a useful marker for tailoring optimal therapies for individual patients with advanced ESCC.","number":"8","journal":"World journal of surgery","author":[{"propositions":[],"lastnames":["Hamai"],"firstnames":["Yoichi"],"suffixes":[]},{"propositions":[],"lastnames":["Hihara"],"firstnames":["Jun"],"suffixes":[]},{"propositions":[],"lastnames":["Taomoto"],"firstnames":["Junya"],"suffixes":[]},{"propositions":[],"lastnames":["Yamakita"],"firstnames":["Ichiko"],"suffixes":[]},{"propositions":[],"lastnames":["Ibuki"],"firstnames":["Yuta"],"suffixes":[]},{"propositions":[],"lastnames":["Okada"],"firstnames":["Morihito"],"suffixes":[]}],"month":"August","year":"2014","pmid":"24615604","keywords":"Adult, Aged, Biomarkers, Tumor, Carcinoma, Squamous Cell, Chemoradiotherapy, Combined Modality Therapy, Esophageal Neoplasms, Esophagectomy, Female, Hemoglobins, Humans, Male, Middle Aged, Neoadjuvant Therapy, Retrospective Studies, Survival Rate, Treatment Outcome","pages":"2046–2051","bibtex":"@article{hamai_hemoglobin_2014,\n\ttitle = {Hemoglobin level influences tumor response and survival after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma},\n\tvolume = {38},\n\tissn = {1432-2323},\n\tdoi = {10.1007/s00268-014-2486-2},\n\tabstract = {BACKGROUND\n\nNeoadjuvant chemoradiotherapy (nCRT) followed by esophagectomy confers a survival benefit on patients with esophageal cancer. However, nCRT might be less meaningful for poor responders. Thus, being able to predict responses would help ensure the selection of optimal therapy.\n\n\nMETHODS\n\nWe reviewed data from 123 patients with esophageal squamous cell carcinoma (ESCC) who underwent nCRT that comprised concurrent radiation (40 Gy) and chemotherapy followed by esophagectomy. We assessed associations between clinical and blood data obtained before starting nCRT and the pathologic response.\n\n\nRESULTS\n\nWe compared good (Japan Esophageal Society response evaluation criteria grades 3/2; n = 89, 72.4\\%) and poor (grades 1/0; n = 34, 27.6\\%) responders. Performance status (p = 0.02), hemoglobin level (p = 0.005), and platelet counts (p = 0.03) were statistically significant pretherapeutic factors for a response to nCRT. Multivariable analysis subsequently selected the hemoglobin level (odds ratio 1.52; 95\\% confidence interval 1.08-2.15; p = 0.02) as the sole independent predictor. Receiver operating characteristic curves showed that the optimal cutoff for pretherapeutic hemoglobin was 13 g/dl for predicting a response. We found that 48.8 and 17.1\\% of patients with hemoglobin level ≤13 and {\\textgreater}13 g/dl, respectively, were poor responders (p = 0.0002), with 5-year overall survival rates of 40.9 and 58.9\\%, respectively (p = 0.048).\n\n\nCONCLUSIONS\n\nPretherapeutic hemoglobin levels can influence responses and survival after nCRT for ESCC. Thus, hemoglobin levels can serve as a useful marker for tailoring optimal therapies for individual patients with advanced ESCC.},\n\tnumber = {8},\n\tjournal = {World journal of surgery},\n\tauthor = {Hamai, Yoichi and Hihara, Jun and Taomoto, Junya and Yamakita, Ichiko and Ibuki, Yuta and Okada, Morihito},\n\tmonth = aug,\n\tyear = {2014},\n\tpmid = {24615604},\n\tkeywords = {Adult, Aged, Biomarkers, Tumor, Carcinoma, Squamous Cell, Chemoradiotherapy, Combined Modality Therapy, Esophageal Neoplasms, Esophagectomy, Female, Hemoglobins, Humans, Male, Middle Aged, Neoadjuvant Therapy, Retrospective Studies, Survival Rate, Treatment Outcome},\n\tpages = {2046--2051}\n}\n\n","author_short":["Hamai, Y.","Hihara, J.","Taomoto, J.","Yamakita, I.","Ibuki, Y.","Okada, M."],"key":"hamai_hemoglobin_2014","id":"hamai_hemoglobin_2014","bibbaseid":"hamai-hihara-taomoto-yamakita-ibuki-okada-hemoglobinlevelinfluencestumorresponseandsurvivalafterneoadjuvantchemoradiotherapyforesophagealsquamouscellcarcinoma-2014","role":"author","urls":{},"keyword":["Adult","Aged","Biomarkers","Tumor","Carcinoma","Squamous Cell","Chemoradiotherapy","Combined Modality Therapy","Esophageal Neoplasms","Esophagectomy","Female","Hemoglobins","Humans","Male","Middle Aged","Neoadjuvant Therapy","Retrospective Studies","Survival Rate","Treatment Outcome"],"downloads":0},"bibtype":"article","biburl":"https://api.zotero.org/users/585595/collections/74C3SXBK/items?key=1nXMl6HeUfXzWafuqAa4Ryj2&format=bibtex&limit=100\"></iframe","creationDate":"2019-05-09T15:52:34.266Z","downloads":0,"keywords":["adult","aged","biomarkers","tumor","carcinoma","squamous cell","chemoradiotherapy","combined modality therapy","esophageal neoplasms","esophagectomy","female","hemoglobins","humans","male","middle aged","neoadjuvant therapy","retrospective studies","survival rate","treatment outcome"],"search_terms":["hemoglobin","level","influences","tumor","response","survival","neoadjuvant","chemoradiotherapy","esophageal","squamous","cell","carcinoma","hamai","hihara","taomoto","yamakita","ibuki","okada"],"title":"Hemoglobin level influences tumor response and survival after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma","year":2014,"dataSources":["Eax3HqcG6fcDtsCq9"]}